Neurolixis Awarded Grant from the Rett Syndrome Research Trust

Dana Point, 15 April, 2014 -- Neurolixis Inc. announced that it has been awarded a research grant by the Rett Syndrome Research Trust (RSRT) to support the development of its novel serotonin 5-HT1A receptor agonist, NLX-101. This award will help support pharmacokinetic studies in animals and computer modeling to predict doses for a clinical study in Rett patients.

Rett syndrome is a rare neurological disorder, affecting 1 in 10,000 female births. The syndrome only manifests itself when children are 1-2 years of age: girls then develop autistic-like behaviors, lose control of their muscles, lose speech and stop walking. Most children with Rett syndrome go on to develop breathing irregularities, epilepsy, anxiety, scoliosis and deformity in their extremities due to abnormal muscle control, among other health problems.

Dr. Mark Varney, Chief Executive Officer of Neurolixis commented, "We thank the RSRT for their financial support to this program, and are honored to be the first industry recipient of an award. This grant will help us to identify the appropriate doses of NLX-101 for a future clinical study in Rett syndrome patients. Given the levels of disability of Rett patients, new treatments such as NLX-101 need to be dosed carefully in this patient population."

About NLX-101

NLX-101 acts on the brain's serotonin system, and exhibits preferential activation of 5-HT1A receptors located in specific regions of the brain: such 'biased agonism' in these brain regions is thought to underlie its potent effects in animal models of Rett syndrome (see Levitt ES et al., Journal of Applied Physiology, Oct 10, 2013). NLX-101 is an orally administered agent that has previously been tested in a Phase 1 clinical study in healthy volunteers. Neurolixis plans to investigate its ability to normalize irregular breathing patterns and other functions in patients with Rett syndrome.

About Rett Syndrome

Rett syndrome is a rare childhood neurological disorder that primarily affects girls. Most babies with Rett syndrome develop normally at first, with symptoms appearing between 6 and 18 months of age. Children with Rett syndrome develop a wide range of symptoms that include abnormal and distressing breathing patterns, as well as loss of speech and poor movement coordination. There is no cure for Rett syndrome. The incidence of Rett is estimated at 1 in 10,000 females; worldwide there are approximately 350,000 girls and women affected with Rett syndrome.

About the Rett Syndrome Research Trust

The Rett Syndrome Research Trust is a non-profit exclusively devoted to global research on Rett Syndrome and related MECP2 disorders. Our goal is to heal children and adults who will otherwise suffer the effects of these disorders for the rest of their lives. To learn more about the Trust, please visit www.ReverseRett.org

About Neurolixis, Inc.

Neurolixis, located in Dana Point, California, is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of neurological disorders such as Rett syndrome and Parkinson's disease, and psychiatric disorders such as depression and schizophrenia. Additional information regarding Neurolixis is available at www.neurolixis.com

Forward Looking Statement

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.

PRESS CONTACTS

Dr Mark Varney, CEO Neurolixis,
mvarney@neurolixis.com